64O_PR - High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: A case-control study
|Date||17 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Breast Cancer, Early Stage
Imaging, Diagnosis and Staging
Surgery and/or Radiotherapy of Cancer
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575|
Y. Huang1, J.L. Chen2, S. Kuo3, Y. Chang1
We aimed to evaluate the influence of mammographic breast density at diagnosis on the risk of cancer recurrence and survival outcomes in patients with invasive breast cancer after modified radical mastectomy.
This case-control study included 123 case-control pairs of women diagnosed with invasive breast cancer between 2004 and 2009 who had undergone modified radical mastectomy and had mammographic breast density measured before or at diagnosis. Women with known locoregional recurrence or distant metastasis were matched to women without recurrence by pathological disease stage, age, year of diagnosis, hormone receptor status, Her2 status, and adjuvant hormone or trastuzumab administration. Locoregional recurrence included recurrence in the ipsilateral breast, axillary or supraclavicular nodes, or contralateral breast. The median follow-up duration was 60.8 months for case patients and 61.3 months for control patients.
Patients with heterogeneously dense (50–75% density) and extremely dense breasts (>75% density) had an increased risk of locoregional recurrence (hazard ratios, 3.9 and 8.4; 95% conﬁdence intervals, 1.1–14.1 and 1.4–67.6; and p = 0.033 and 0.024, respectively). Multivariate analysis that included a lack of adjuvant radiotherapy and triple negative cancer revealed that dense breasts (>50% density) remained a significant factor for predicting locoregional recurrence risk (hazard ratio, 4.9; 95%; conﬁdence interval, 1.4–17.3; and p = 0.013).
Our results demonstrate that dense breast tissue (>50% density) conferred a greater risk of locoregional recurrence after modified radical mastectomy in patients with invasive breast cancer. Additional prospective studies are necessary to validate these ﬁndings.
Clinical trial indentification
Legal entity responsible for the study
National Taiwan University Hospital
Ministry of Science and Technology (MST, Taiwan, under contract of MST 105-2314-B-002-022-)
All authors have declared no conflicts of interest.